1. Joelsson J, Wasterlid T, Rosenquist R, et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv 2022; 6: 2657-2666.
2.
Fianchi L, Criscuolo M, Fabiani E, et al. Therapy-related myeloid neoplasms: clinical perspectives. Onco Targets Ther 2018; 11: 5909-5915.
3.
Al-Juhaishi T, Khurana A, Shafer D. Therapy-related myeloid neoplasms in lymphoma survivors: reducing risks. Best Pract Res Clin Haematol 2019; 32: 47-53.
4.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
5.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.
6.
Borthakur G, Estey AE. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 2007; 9: 373-377.
7.
Greim H, Kaden DA, Larson RA, et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci 2014; 1310: 7-31.
8.
Gertz MA, Terpos E, Dispenzieri A, et al. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leuk Lymphoma 2015; 56: 1723-1726.
9.
Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma. Cancer Res 1983; 43: 1891-1898.
10.
Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010; 28: 4935-4944.
11.
Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol 2003; 21: 897-906.
12.
Rosner F, Grunwald H. Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. Am J Med 1974; 57: 927-939.
13.
Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353.
14.
Fenk R, Neubauer F, Bruns I, et al. Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Br J Haematol 2012; 156: 683-686.
15.
McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
16.
Attal M, Cances Lauwers V, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02. Blood 2010; 116: 310.
17.
Jones JR, Cairns DA, Menzies T, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine 2023; 62: 102099.
18.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-2465.
19.
Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 2013; 88: 317-327.
20.
Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomar- ker cutoff optimization. PLoS One 2012; 7: e51862.
21.
Bertoli S, Sterin A, Tavitian S, et al. Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget 2016; 7: 85937-85947.
22.
Maung SW, Burke C, Hayde J, et al. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience. Hematology 2017; 22: 341-346.
23.
Puertas B, González-Calle V, Sobejano-Fuertes E, et al. Novel agents as main drivers for continued improvement in survival in multiple myeloma. Cancers 2023; 15: 1558.
24.
Sahebi F, Iacobelli S, Sbianchi G, et al. Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents. Biol Blood Marrow Transplant 2018; 24: 930-936.
25.
Wang J, Lv C, Zhou M, et al. Second primary malignancy risk in multiple myeloma from 1975 to 2018. Cancers 2022; 14: 4919.
26.
Pemmaraju N, Shah D, Kantarjian H, et al. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2015; 15: 110-114.
27.
Larson RA. Therapy-related myeloid neoplasms. Haematologica 2009; 94: 454-459.
28.
Larson RA. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2300-2302.
29.
Adamska M, Kowal-Wisniewska E, Przybylowicz-Chalecka A, et al. Clinical outcomes of therapy-related acute myeloid leukemia: an over 20-year single-center retrospective analysis. Pol Arch Intern Med 2023; 133: 16344.
30.
Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850-1857.
31.
Koontz MZ, Horning SJ, Fau-Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013; 31: 592-598.
32.
Valagussa P, Santoro A, Fossati Bellani F, et al. Absence of treatment-induced second neoplasms after ABVD in Hodgkin’s disease. Blood 1982; 59: 488-494.
33.
Brusamolino E, Anselmo AP, Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin’s disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998; 83: 812-823.
34.
Pedersen-Bjergaard J. Insights into leukemogenesis from therapy- related leukemia. N Engl J Med 2005; 352: 1591-1594.
35.
Ornstein MC, Mukherjee S, Mohan S, et al. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Am J Hematol 2014; 89: 168-173.
36.
Hake CR, Graubert TA, Fenske TS. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007; 39: 59-70.
37.
Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999; 106: 1020-1026.
38.
Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90: E80-5.